Kensai Health transforms complex clinical data into clear scientific storytelling that drive informed decisions and regulatory strategy to bring innovations from data to approval.
In modern clinical drug development, the greatest threat to project timelines is not scientific ambiguity, but the operational disconnect between statistical data and regulatory documentation.
Large full-service CROs frequently bundle medical writing as an afterthought, pitching seasoned medical writers for critical deliverables. The consequence: misaligned SAPs, flawed statistical tables, lengthy comment resolution rounds, and months of delayed submission milestones.
Kensai Health was established to eliminate this bottleneck. Headquartered in Singapore, we operate as a specialized clinical consultancy providing direct, senior-level authoring, proactive biostatistical oversight, and consensus-driven stakeholder management.
Founder & Principal Consultant • Ph.D. (Management) • MBA (Operations) • M.Pharm (Hospital Pharmacy)
Dr. Kavita R. Garg is a seasoned Medical Communication and Clinical Regulatory Writing leader with more than 23 years of international pharmaceutical and CRO industry experience. Throughout her career, she has led, authored, and reviewed clinical and regulatory submission documents across the US, EU, APAC, Middle East, and Southeast Asia.
Her professional trajectory includes senior roles at premier life sciences organizations, such as Saliegral Global, Accelsiors CRO and Consultancy, INC Research (Syneos Health Clinical), SIRO Clinpharm, and Ranbaxy Laboratories Limited (Sun Pharma).
Beyond corporate leadership, Dr. Garg is an active contributor shaping global regulatory writing standards and mentoring the next generation of life sciences communicators:
Why operating from Asia's premier biomedical innovation hub empowers our global clients.
Singapore consistently ranks #1 in Asia and among the top globally for intellectual property protection and legal integrity, safeguarding proprietary trial protocols, CSR data, and patent-sensitive disclosures.
Kensai Health supports bridging the timezone gap across Americas, Europe, and Asia-Pacific by providing active coverage when Western teams sign off, accelerating document turnaround cycles overnight.
Complete familiarity with Health Sciences Authority (HSA Singapore), US FDA, and European Medicines Agency (EMA) ensures all submissions adhere to global ICH, GCP, and eCTD standards.
